Differential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffness

International Angiology

Volumn 29, Issue 3, 2010, Pages 266-272

  Andreadis, E A ^a   Sfakianakis, M E ^a   Tsourous, G I ^a   Georgiopoulos, D X ^a   Fragouli, E G ^a   Katsanou, P M ^a   Tavoularis, E I ^a   Skarlatou, M G ^a   Marakomichelakis, G E ^a   Ifanti, G K ^a   Diamantopoulos, E J ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Angiotensin II type 1 receptor blockers; Blood pressure monitoring, ambulatory; Calcium channel blockers; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; FELODIPINE; IRBESARTAN; LACIDIPINE; LOSARTAN; TELMISARTAN; VALSARTAN;

ADULT; ANKLE EDEMA; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ARTERIES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; ELASTICITY; FEMALE; GREECE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956088175     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laboux B, Boutouyrie P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003;34:1203-1206. (Pubitemid 36547514)
2. Kikuya M, Staessen JA, Ohkubo T, Thijs L, Metoki H, Asayama K, Obara T, Inoue R, Li Y Dolan E, Hoshi H, Hashimoto J, Totsunek K, Satoh H. Ambulatory arterial stiffness index and 24-hour ambulatory pulse pressure as predictors of mortality in Ohasama Japan. Stroke 2007;38:1161-1166.
3. Dolan E, Thijs L, Li y, Atkins N, McCormack P, McClory S, O'Brien E, Staessen JA, Stanton AV. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin outcome study. Hypertension 2006;47:365-370.
4. Hanseen TW, Staessen JA, Torp-Pedersen C, Rasmussen C, Li Y, Dolan E, Thiys L, Wang JG, O'Brien E, Ibsen H, Jeppessen J. Ambulatory arterial stiffness index predicts stroke in a general population. J Hypertens 2006;24:2247-2253.
5. Schillaci G, Parati G, Pirro M, Pucci G, Mannarino M, Sperandini L, Mannarino E. Ambulatory arterial stiffness index is not a specific marker of reduced arterial compliance. Hypertension 2007;49:986-991.
6. Schillaci G, Parati G. Ambulatory arterial stiffness index: merits and limitations of a simple surrogate measure of arterial compliance. J Hypertens 2008;26:182-185.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ,and the National High Blood Pressure Education Program Coordinating Committee. Seven Report of the Join National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure. Hypertension 2003;42:1206-1252.
8. Friedwald WT, Levy RI, Fredrickson DS: Estimation of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
9. Hainline A Jr, Karon G, Lippel K (eds): Manual of Laboratory Operations, ed.2, Lipid Research Clinics Program, Lipid and Lipoprotein Analysis, Washington DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health (updated 1983).
10. Association for the Advancement of Medical Instrumentation. American national standards for electronic and automated sphygmomanometers. AAMI, Washington, DC, 1987.
11. Andreadis EA, Tsourous GI, Marakomichelakis GE, Katsanou PM, Fotia ME, Vassilopoulos CV, Diamantopoulos EJ. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptors blockers in mild to moderate hypertension. J Hum Hypertens 2005;19:401-496.
12. Asmar RG. Noninvasive evaluation of arterial abnormalities in hypertensive subjects. Pathol Biol 1999;47:685-695.
13. Laurent S, Herpin D, de Gaudemaris R, Laude D, Vaisse B. The best of hypertension in 2002. Arch Mal Cœur Vaiss 2003 ;1 :9-13.
14. Agabiti-Rosei E, Heagerty A, Rizzoni D. Effects of antihypertensive treatment on small artery remodelling. J Hypertens 2009;27:1107-1114.
15. Smith RD, Yokoyama H, Averill DB, Schiffrin EL, Ferrario SM. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J Am Soc Hypertens 2008;165-172. (Pubitemid 351699665)
16. Smith RD, Yokoyama H, Averill DB, Cooke L, Brosnihan KB, Schiffrin EL, Ferrario CM. The protective effect of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodelling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006;6:335-342. (Pubitemid 44749343)
17. Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008;51:1-7
18. Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertens 2009;27:941-946.
19. Sasamura H, Kitamura Y, Nakamura M, Ryuzaki M, Saruta T. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension Clin Exp Hypertens 2006;28:511-520.
20. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88:1L-20L.
21. Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotension-aldosterone system in hypertension and diabetes J Hum Hypertens 2006;20:239-253.
22. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Circulation 2006;113:1213-1225.